Onxeo S.A. announced the presentation of new preclinical data confirming the relevance of combining AsiDNA with PARP inhibitors (PARPi) in homologous recombination repair (HRP) tumor models, during poster and oral sessions at the ESMO Targeted Anticancer Therapies Congress (7-8 March, 2022). Although PARP inhibitors have shown significant benefits in cancer patients with deficient homologous recombination repair (HRD), they show no or very limited efficacy in tumors with active or proficient homologous recombination repair (HRP). The data presented by Onxeo highlight the therapeutic opportunity of combining AsiDNA and PARPi in HRP tumors to overcome intrinsic or acquired resistance in clinical situation.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.11 EUR | -2.65% | -6.78% | -33.33% |
2023 | Valerio Therapeutics Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
2023 | Onxeo SA has Changed its Name to Valerio Therapeutics | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-33.33% | 18.09M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- ALVIO Stock
- News Valerio Therapeutics
- Onxeo’s New Preclinical Data Confirm the Relevance of Combining AsiDNA™ With PARP Inhibitors in Treating Homologous Recombination Proficient Tumors